๐ฎ๐ฌ๐ญ๐ณ: Unlearn founded.
๐ฎ๐ฌ๐ญ๐ต: First FDA interaction on digital twins.
๐ฎ๐ฌ๐ฎ๐ฎ: EMA qualification opinion for PROCOVA.
๐ฎ๐ฌ๐ฎ๐ณ: What weโre building now for sponsors.
Ten years of deploying digital twins in clinical development, from single-study gains to portfolio decisions, in 45 minutes plus live Q&A with Dr. Jon Walsh, Ian Fleming and Dr. Luis Olmos.
๐ Monday, December 7, 10 AM PT
๐ Register: na2.hubs.ly/H091LJV0
55
Obesity drugs work. The question sponsors face now is how they compare, and a head-to-head trial is an expensive way to find out: a huge commitment to one comparator, one population, and one set of outcomes. Almost nobody runs one.
In the final post of his obesity in clinical trials series, our co-founder and Chief Scientific Officer Jon Walsh looks at how teams can understand where their drug fits, from the limits of comparing published results to simulating comparisons with digital twins, and how to decide which head-to-head is worth running.
Read the full post: na2.hubs.ly/H091LJg0
#Obesity #ClinicalTrials #DigitalTwins #ClinicalDevelopment
1
90
Thatโs a wrap on #ObesityWeek2026! ๐
Great to see our work with @StructureTx in the ACCESS open-label extension poster for aleniglipron. Thank you to everyone who stopped by to talk about where obesity trials are headed and how digital twins can help teams make better decisions at every stage.
#Obesity #ClinicalTrials #DigitalTwins
โโโ
@ObesityWeek
1
3
155
What can AI-generated digital twins tell us about longer-term obesity study data?
Thatโs the question behind Unlearnโs collaboration with @StructureTx, announced today.
Using anonymized data from Structureโs completed ACCESS open-label extension study of aleniglipron, weโll estimate what patient outcomes might have been without the investigational treatment. These model-generated estimates are what we call โdigital twins.โ
Comparing those estimates with observed outcomes may provide additional context for interpreting the studyโs longer-term findings.
Data from our analysis will be included in the poster โAleniglipron in Participants Living with Overweight or Obesity: ACCESS Trial Open-Label Extensionโ at ObesityWeek.
โก๏ธ Read the announcement: na2.hubs.ly/H08-25x0
1
108
๐ Unlearn is heading to Boston for #CTAD2026, November 16โ19.
Alzheimerโs sponsors face big decisions at every stage of a trial: settling on eligibility and endpoints, sharpening an interim analysis, or working out what a completed study means for the next one. Digital twins help teams make each of those calls with more confidence.
In a completed Phase 2 RCT in early Alzheimerโs, adding participantsโ digital twins reduced the required sample size by 15%, or the control-arm size by 26%, with power maintained on CDR-SB at week 96. That analysis used PROCOVA, a method qualified by the EMA and supported by FDA guidance.
Whether your study is in design, in progress, or has already read out, letโs talk at CTAD.
See our Alzheimerโs work: na2.hubs.ly/H08ZdKC0 (na2.hubs.ly/H08ZdKC0)
#Alzheimers #ClinicalTrials #DigitalTwins #AI #ClinicalDevelopment
โโโ
@CTADconference
The hardest part isnโt the model. A decade of deploying #digitaltwins has taught us itโs making messy #clinicaldata usable, with a record that holds up to scrutiny.
On December 7, Dr. Jon Walsh, Ian Fleming and Dr. Luis Olmos will share what weโre building for sponsors now: one foundation where historical data are unified, harmonized, and used to create and apply digital twins across every program decision.
45 minutes of discussion, plus live Q&A.
๐ Monday, December 7, 10 AM PT
๐ Register: na2.hubs.ly/H08TbbL0
1
103
๐ Jon Walsh, Co-founder and Chief Scientific Officer, and Luis Olmos, Senior Director of Clinical Affairs, are at ARPA-Hโs SURPASS Proposersโ Day in Washington, DC today.
SURPASS (Simulation-augmented, Real-time Platform Adaptive Seamless Trials) aims to replace phase-by-phase studies with continuous, adaptive trials that have simulation built into the design.
We share that vision. Every clinical trial is a chain of high-stakes decisions, and digital twins, data, and AI can strengthen each one. With Unlearn, teams can simulate a trial before they commit, sharpen interim analyses with our EMA-qualified, FDA-supported PROCOVA method, and get more from completed studies so each readout informs the next design.
If youโre at Proposersโ Day, come find us. Weโd love to talk about where digital twins fit in the future of clinical trials.
#ARPAH #SURPASS #ClinicalTrials #DigitalTwins
โโโ
@ARPA_H
156
From single-study gains to portfolio decisions: a decade of learnings from deploying digital twins in clinical development. ๐
Every clinical trial is an expensive bet and digital twins offer a better way. The question is no longer whether they belong in clinical development, but how to use them well. A decade of deploying them has taught us that the hardest part isnโt the model but making messy clinical data usable, with a record that holds up to scrutiny.
On December 7, Dr. Jon Walsh (Co-founder & Chief Scientific Officer, Unlearn) sits down with Dr. Luis Olmos (Senior Director of Clinical Affairs, Unlearn) and Ian Fleming (VP of Product) to share how those lessons became what sponsors asked us to build: one foundation where historical data are unified, harmonized, and used to create and apply digital twins across every program decision. Every result traceable, every study informing the next.
45 minutes of discussion, plus live Q&A.
๐ Monday, December 7, 10 AM PT
๐ Register: na2.hubs.ly/H08R39x0
82
Thank you to everyone who met with us at #ESMO2026 in Madrid last week! ๐ช๐ธ
Many oncology indications now have several standard-of-care regimens that have never been compared head-to-head, and probably never will be. That topic came up again and again in our meetings. Trial-calibrated digital twins can make that comparison at the patient level.
Interested in learning more? Weโre at SITC in Phoenix this week. Letโs connect! ๐
#SITC2026 #Oncology #DigitalTwins
โโโ
@myESMO, @sitcancer
1
156
Our Senior Director of Clinical Affairs, Luis Olmos, recently presented at the KoNECT International Conference in South Korea. ๐ฐ๐ท
His session, โ๐๐ ๐ฎ๐ป๐ฑ ๐๐ถ๐ด๐ถ๐๐ฎ๐น ๐ง๐๐ถ๐ป๐ ๐ถ๐ป ๐๐น๐ถ๐ป๐ถ๐ฐ๐ฎ๐น ๐๐ฒ๐๐ฒ๐น๐ผ๐ฝ๐บ๐ฒ๐ป๐: ๐๐ฟ๐ผ๐บ ๐๐ป๐ป๐ผ๐๐ฎ๐๐ถ๐ผ๐ป ๐๐ผ ๐ฅ๐ฒ๐ด๐๐น๐ฎ๐๐ผ๐ฟ๐ ๐ฎ๐ป๐ฑ ๐ฅ๐ฒ๐ฎ๐น-๐ช๐ผ๐ฟ๐น๐ฑ ๐๐บ๐ฝ๐น๐ฒ๐บ๐ฒ๐ป๐๐ฎ๐๐ถ๐ผ๐ป,โ explored how digital twins can increase statistical power in randomized trials through PROCOVA, support synthetic external controls where randomization is not feasible, and what EMA qualification of PROCOVA means for clinical development.
We appreciate KoNECT for the opportunity to share our work and the attendees for a valuable discussion.
#KoNECT #DigitalTwins #ClinicalTrials #ClinicalDevelopment
2
164
Back from NEALS 2026 in Clearwater, and grateful for every conversation. ๐ด
We connected with ALS researchers, clinicians, and sponsors about how digital twins can help small and early-phase studies deliver clearer, more trustworthy readouts.
We also presented our poster, โ๐๐-๐๐ฒ๐ป๐ฒ๐ฟ๐ฎ๐๐ฒ๐ฑ ๐๐ถ๐ด๐ถ๐๐ฎ๐น ๐ง๐๐ถ๐ป๐ ๐ฎ๐ป๐ฑ ๐ฃ๐น๐ฎ๐๐บ๐ฎ ๐ก๐ณ๐ ๐ณ๐ผ๐ฟ ๐ง๐ฟ๐ถ๐ฎ๐น ๐ฃ๐น๐ฎ๐ป๐ป๐ถ๐ป๐ด ๐ฎ๐ป๐ฑ ๐ฆ๐๐ฎ๐๐ถ๐๐๐ถ๐ฐ๐ฎ๐น ๐๐ณ๐ณ๐ถ๐ฐ๐ถ๐ฒ๐ป๐ฐ๐ ๐ถ๐ป ๐๐๐ฆ,โ which showed how digital twin adjustment took a trial designed at 50% power up to 72% on key endpoints. Our ALS model is trained on data from more than 13,600 people with ALS and forecasts outcomes on ALSFRS-R, vital capacity, and plasma NfL.
Thank you to everyone who stopped by, and to our partners across the ALS community.
Missed us? Explore more of our ALS work here: na2.hubs.ly/H08JWxn0
#NEALS2026 #ALS #DigitalTwins #ClinicalTrials #AI
1
87
๐ฃ Big shoutout to our Clinical Data Scientist, Ann-Kathrin Schalkamp, who presented โAI-Powered Digital Twins: Applications and Opportunities in Clinical Trialsโ at the EHDN Plenary Meeting in Krakรณw last week.
A participantโs digital twin is a forecast of how that person would progress on placebo, built from their baseline data alone. Added to a randomized trial as a pre-specified covariate, it makes the treatment effect easier to see, using a method EMA qualified in 2022 and FDA concurred with.
Ann-Kathrin showed what that means for trial planning. She took 444 real participants the model had never seen during training, selected with the entry criteria todayโs disease-modifying HD trials use, and checked the modelโs two-year forecasts against what actually happened to them. Sized like a current trial, a study of those 444 people could run with 64 fewer on placebo at the same power. Or keep all 444 and cut the chance of missing a drug that works from one in five to one in eight.
Our Huntingtonโs Digital Twin Generator was trained on clinical data from 25k+ trial participants across Enroll-HD, REGISTRY, TRACK-HD, PREDICT-HD and completed trials. None of it would exist without the people and families who contributed to those studies, and the teams who built them.
Thank you to EHDN and the session chairs for the invitation, and to everyone who stayed for the panel.
More on digital twins in Huntingtonโs disease: na2.hubs.ly/H08B2YS0
#EHDN2026 #HuntingtonsDisease #DigitalTwins #ClinicalTrials
148
Heading to #NEALS2026 in Clearwater? Come find us at Poster #212.
Weโll be presenting โAI-Generated Digital Twins and Plasma NfL for Trial Planning and Statistical Efficiency in ALS,โ including how pre-specified digital twin adjustment (PROCOVA) would take a study designed at 50% power to 67% on ALSFRS-R and 72% on SVC.
๐ Poster #212
๐๏ธ October 29, 4:50โ6:30 PM ET
Stop by, or reach out to find time to connect while weโre there.
#ALS #DigitalTwins #ClinicalTrials
111
#UnlearnerSpotlight ๐ โI love the freedom to propose new ideas and actually see them through, and I get to work alongside incredibly talented people who I learn from every day. Most of all, I like knowing my work helps speed up clinical trials and get treatments to patients faster.โ
118
๐ Obesity drugs now deliver more weight loss than is even desired in most cases, shifting the question from how well a drug works to how easily it can be tolerated.ย
In Part 2 of his obesity in clinical trials series, our co-founder and Chief Scientific Officer Jon Walsh looks at what that means for the future of obesity trials. As more treatments reach the market, dropout and drop-in (placebo patients starting marketed drugs mid-trial) will change, the apparent treatment effect will shrink, and comparing therapies will get harder.
Read the full post: na2.hubs.ly/H08v_0d0
#Obesity #ClinicalTrials #DigitalTwins #ClinicalDevelopment
84
๐ Weโre excited to welcome Ian Fleming as Unlearnโs new VP of Product.
Ian brings 25 years of experience in the life sciences industry. He started with hands-on statistical work on clinical programs, then moved into building the technology that clinical and biometrics teams rely on, most recently building a team that delivered foundational components of a major clinical data platform and its AI infrastructure.
Welcome to the team, Ian!
1
102
Sponsors are no longer asking whether digital twins work. Theyโre asking who builds the infrastructure, what data it runs on, and whether it will hold up when regulators ask about it years from now.
Many internal builds stall on the same three things: single-study models that canโt follow a program as it evolves, the cross-functional alignment needed to get twins into a protocol, and harmonized data that everything else depends on.
In our latest post, we share what weโve learned from working with leading sponsors, including why the right unit for a model is the disease, not the study.
If your team is building this now, or has tried and stalled, weโd like to compare notes.
na2.hubs.ly/H08rdMf0
#DigitalTwins #ClinicalDevelopment #AIinClinicalTrials
92
๐ Our latest whitepaper, A Field Guide to Digital Twins in Clinical Development, walks through each decision point in a study, from eligibility criteria and sample size in design, to stopping rules at interim, to interpreting the result after readout, and shows how digital twins fit at every step.
It also covers the methods behind each use and the deployment principles we follow, drawn from the @FDA's draft guidance on AI in drug development.
Download the field guide: na2.hubs.ly/H08nFyK0
#ClinicalTrials #DigitalTwins #DrugDevelopment #Biostatistics #AI
66
Six years of working with @FDA and @EMA_News on #digitaltwins for #clinicaltrials, summarized. Luis Olmos on where the #regulatory work stands and what it means for your next study: na2.hubs.ly/H08gQnt0
97
One of the biggest problems in #obesity #clinicaltrials today is that placebo patients can figure out their assignment quickly and take action into their own hands if theyโre not losing weight. They can leave the study, or start treatment on their ownโฆall while their results still count toward the placebo arm.
Our co-founder and Chief Scientific Officer, Jon Walsh, wrote about what that does to the data and why the fix belongs in #trialdesign.
Read the post: na2.hubs.ly/H08ftx20
















